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Background: Chronic kidney disease progression has been linked to pro-inflammatory cytokines and markers of
inflammation. These markers are also elevated in end-stage renal disease (ESRD), which constitutes a serious public
health problem.
Objective: To investigate whether single nucleotide polymorphisms (SNPs) located in genes related to immune
and inflammatory processes, could be associated with ESRD development.
Design and methods: A retrospective case-control study was carried out on 276 patients with ESRD and 288
control subjects. Forty-eight SNPs were genotyped via SNPlex platform. Logistic regression was used to assess the
relationship between each sigle polymorphism and the development of ESRD.
Results: Four polymorphisms showed association with ESRD: rs1801275 in the interleukin 4 receptor (IL4R) gene
(OR: 0.66 (95%CI = 0.46-0.95); p= 0.025; overdominant model), rs4586 in chemokine (C-C motif ) ligand 2 (CCL2) gene
(OR: 0.70 (95%CI = 0.54-0.90); p= 0.005; additive model), rs301640 located in an intergenic binding site for signal
transducer and activator of transcription 4 (STAT4) (OR: 1.82 (95%CI = 1.17-2.83); p= 0.006; additive model) and rs7830
in the nitric oxide synthase 3 (NOS3) gene (OR: 1.31 (95%CI = 1.01-1.71); p= 0.043; additive model). After adjusting for
multiple testing, results lost significance.
Conclusion: Our preliminary data suggest that four genetic polymorphisms located in genes related to
inflammation and immune processes could help to predict the risk of developing ESRD.
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The prevalence of chronic kidney disease (CKD) and
end-stage renal disease (ESRD) is growing worldwide,
with the overall prevalence of CKD stages 3-5 being 6.83%
in Spain [1]. Therefore, it constitutes a serious public
health problem, which causes substantial morbidity and* Correspondence: sresino@isciii.es
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distribution, and reproduction in any mediummortality [2]. Traditional risk factors for CKD progres-
sion include persistent proteinuria, dyslipidaemia, hyper-
tension and smoking [3,4]. However, it has been
postulated that non-traditional risk factors, such as oxi-
dative stress, inflammation and immune processes, may
also be important contributors to the pathogenesis of
cardiovascular disease as well as progression to ESRD [5].
The inflammatory response involved in renal damage pro-
duces a release of proinflammatory cytokines and chemo-
kines, which cause an increased inflow of leukocytes,
intensification of interstitial nephritis and progressive
fibrosis [6].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sidered an important determining factor for the appear-
ance and/or progression of ESRD and its complications
[7,8]. Therefore, the study of polymorphisms may help
us to look further into the disease pathogenesis and its
underlying causes, as well as to predict the predispos-
ition to developing the disease in order to identify the
at-risk population. The aim of this study was to investi-
gate whether single nucleotide polymorphisms (SNPs)
located in regions affecting immune and inflammatory
processes could be associated with development of ESRD.
Our preliminary data suggest that four polymorphisms
showed an association with ESRD protection or devel-




A retrospective study was carried out on 276 kidney
transplant recipients (case-group) and 288 normal
subjects (control-group) from the Hospital Clínico
Universitario of Valladolid (Spain). The study was con-
ducted in accordance with the Declaration of Helsinki.
All patients and controls gave their written consent
and the Institutional Ethics Committee approved the
study.
Subjects in the case-group were patients older than 18
with ESRD that received a cadaver renal graft between
December 1995 and October 2008. Subjects from the
control-group were patients that underwent routine ana-
lysis at the hospital and had no evidence of renal path-
ology or other immune or inflammatory diseases.
Individuals were selected to have age and gender distribu-
tion similar to the case-group patients at the time of
transplantation. In this retrospective study, the clinical
data and DNA samples were collected in a transversal
way for both the case-group and the control-group be-
tween June 2008 and December 2008. In order to ensure
homogeneity, all patients were Caucasian.
DNA extraction, marker selection and genotyping
DNA was extracted from whole blood by the Chemagic
Magnetic Separador Module1, CHEMAGENW which uses
a magnetic particles system to obtain DNA. The quantity
of recovered DNA was quantified by using PicoGreenW
dsDNA Quantitation Reagent (Molecular Probes, Inc.,
Eugene, Oregon, USA).
All SNPs were genotyped at the Spanish National
Genotyping Centre (CeGen; http://www.cegen.org/) by the
SNPlex genotyping system 48-plex (Applied Biosystems,
FosterCity, CA,USA) following themanufacturer’s recom-
mended protocol (http://www3.appliedbiosystems.com/
cms/groups/mcb_support/documents/generaldocuments/
cms_042019.pdf ). As quality control, two Centre d’Etudedu Polymorphisme Humain (CEPH) samples (NA10860
and NA10861) from the HapMap database were included
in all genotyping assays [9].
Published SNPs were selected by different criteria (see
Additional file 1: Table S1 Content 1): SNPs associated
with kidney disease or kidney complications in previous
articles and/or SNPs located in genes involved in genetic
pathways related to prevention or susceptibility to ESRD
(inflammatory and immune processes),. With this purpose
several databases were consulted: International HapMap
Project (www.hapmap.org), dbSNPdatabases (http://www.
ncbi.nlm.nih.gov/SNP/), as well as pathway databases
such as GeneOntology (http://www.geneontology.org/)
and KEGG (http://www.genome.jp/kegg/pathway.html).
Besides, for each significant SNP, the biological implica-
tions were analyzed "in silico" via web-tools: SMART
(http://smart.embl-heidelberg.de/) for identifying the pro-
tein domains, PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/)
for analyzing protein secondary structure prediction,
SIFT (http://blocks.fhcrc.org/sift/SIFT.html) for studying
the amino acid change toleration, PATROCLES (http://
www.patrocles.org/) for identifying putative microRNA
binding sites, PROMO (http://alggen.lsi.upc.es/) for tran-
scription factor binding site prediction and Human Spli-
cing Finder v2.4.1 (http://www.umd.be/HSF/) for studying
the pre-mRNA splicing sites.Statistical analysis
In the control group, Hardy-Weinberg equilibrium
(HWE) was assessed for each polymorphism using the
Pearson Chi-square (χ2) statistic. Only SNPs that ob-
served HWE were included in association analysis.
Unconditional logistic regression was used to assess
the relationship between each single polymorphism and
the development of ESRD. Five genetic models were fit-
ted (dominant, co-dominant, over-dominant, recessive,
and log-additive model). For each SNP, likelihood ratio
test (LRT), and Akaike's information criteria (AIC) were
used as measures of the goodness of fit between models
and to choose the inheritance model that best fits the
data. The next equation defines the logistic model: log
(p/1-p) =α+ βG+ yZ; with p being the probability, G the
categorical variable with the polymorphisms codified, Z
the variables to adjust the model (α, β and γ must be esti-
mated). Odds ratios (OR) and 95% confidence intervals
(CI) were calculated to check the relative risk for asso-
ciation. This model was adjusted for age and gender by
SNPStats (http://bioinfo.iconcologia.net/SNPStats_web)
[10] (p-value< 0.05 was considered significant). More-
over, multiple testing corrections were performed by
SFDR (Stratified False Discovery Rate) software version
1.6. (http://www.utstat.utoronto.ca/sun/Software/SFDR/
index.html).
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Table 1 shows the clinical characteristics of all cases and
controls. The median age and male female ratio were
similar between groups. The most predominant primary
disease involving renal failure was glomerulonephritis
(30%).
From 48 SNPs, the genotyping assay for six SNPs
did not work (rs1570360, rs1808593, rs2070744, rs4762,
rs5498, rs55634318); one SNPwasmonomorphic (rs175176);
and five SNPs (rs1799969, rs1800471, rs1800871, rs4311,
rs699) were discarded because they exceeded 10% of
missing values. Therefore, we analyzed 36 SNPs, all of
which fulfilled the minimum allele frequency (MAF)
>0.05 for all samples and were in HWE in the control
group.
Significant association with ESRD was found for 4
SNPs (Table 2): AG genotype of rs1801275 in interleukin
4 receptor (IL4R) showed reduced odds of ESRD assum-
ing an overdominant model (adjusted OR= 0.66 (95%
CI = 0.46-0.95), p = 0.025). In the case of rs4586 in che-
mokine (C-C motif ) ligand 2 (CCL2), the presence of
each additional copy of the minor allele was associated
with reduced odds of ESRD (adjusted OR=0.70 (95%
CI = 0.54-0.90), p = 0.005) in a log-additive model. On
the other hand, rs301640 in an intergenic binding site
for signal transducer and activator of transcription 4
(STAT4) and rs7830 in nitric oxide synthase 3 (NOS3)
were associated with elevated odds of ESRD assuming a
log-additive model (adjusted OR= 1.82 (95%CI = 1.17-
2.83), p = 0.006; and adjusted OR= 1.31 (95%CI = 1.01-
1.71), p = 0.043, respectively). After applying the false
discovery rate (FDR) for multiple test correction, we ob-
tained that adjusted p values for each hypothesis testing
were no significant (q-value> 0.05). Allelic and genotypicTable 1 Clinical characteristics of patients with ESRD
(cases) and control group
Case group Control group p value
No. 276 288
Age a 50.0 ± 0.78 52.8 ± 1.03 0.030
Male b 108 (39.1%) 119 (41.3%) 0.573
Primary disease b
Glomerulonephritis 82 (29.7%) NA -
Arterial hypertension 30 (10.9%) NA -
Diabetic nephropathy 20 (7.2%) NA -
Tubulointerstitial nephritis 28 (10.1%) NA -
Obstructive uropathy 11 (4.0%) NA -
Vascular causes 5 (1.8%) NA -
Polycystic kidney disease 37 (13.4%) NA -
Others 63 (22.8%) NA -
a Mean± standard error of mean (s.e.m.). b Absolute number (percentage). NA:
not applicable.frequencies of significant SNPs are showed in Additional
file 2: Table S2 Content 2.
Discussion
It has been previously shown that biomarkers of inflam-
mation are high even in the early stages of CKD
[11,12]. The increased inflammation could be caused by
both genetic predisposition and environmental factors,
being linked to the risk of CKD progression to ESRD.
In our study, we have found strong suggestion of asso-
ciations between ESRD and four SNPs located in IL4R
(rs1801275), CCL2 (rs4586), NOS3 (rs7830), and an inter-
genic binding site for STAT4 (rs301640). All of these sites
involve genes related to inflammation and immune re-
sponse pathways.
On the one hand, two of the significant SNPs
(rs1801275, and rs4586) reflected a certain protection
against ESRD:
a) rs1801275 (A/G) is located at position g.54150A>G
of the IL4R gene in chromosome 16. This position
corresponds to exon 12, where it generates a
missense change (p.Gln576Arg). IL-4 is a cytokine
involved in Th2 immune response, and its effect
depends on binding with IL4R. IL-4 has been found
to be an important predictor of kidney injury.
Modulation of the IL4 pathway during ESRD may be
due to an intracellular regulation involving different
pathways but also could be possible that
polymorphisms within the IL4R gene could alter the
signalling pathway of IL-4, leading to a progression
or prevention of kidney damage [13]. In our study,
the presence of the AG genotype seems to indicate
protection from ESRD development, which could be
caused by a decrease in signalling of IL-4 through of
its receptor. Although rs1801275 is a missense SNP
which is located in a low complexity domain of the
protein (SMART) and it has been predicted as
tolerant (SIFT). To date, this SNP has shown
associations with inflammatory and autoimmune
diseases such as arthritis rheumatoid, asthma,
allergic diseases and atopy [14,15], but the entire
role in CKD of IL-4 and its signalling pathway
through IL4R still remains unknown and further
studies are needed.
b) rs4586 (C/T) is a synonymous polymorphism
located on exon 2 of the CCL2 gene in chromosome
17. The CCL2 gene encodes a key chemokine in
recruiting mononuclear inflammatory cells to sites
of inflammation. One example is the interstitium
and glomerulus, where CCL2 causes renal interstitial
and glomerular inflammation, leading to progressive
renal injury [16]. In our study, the presence of each
additional copy of the C allele of rs4586 indicates
Table 2 Summary of logistic regression of SNPs with ESRD
SNP Gene Inheritance model Genotypes OR (95% CI)a p-valuea
rs1801275 IL4R Overdominant A/A-G/G 1.00
A/G 0.66 (0.46-0.95) 0.025
rs301640 STAT4 binding site Log-additive A 1.82 (1.17-2.83) 0.0064
rs4586 CCL2 Log-additive C 0.70 (0.54-0.90) 0.0051
rs7830 NOS3 Log-additive T 1.31 (1.01-1.71) 0.043
Abbreviations: ESRD, end-stage renal disease; IL4R, interleukin 4 receptor; STAT4 signal transducer and activator of transcription 4; CCL2, chemokine (C-C motif)
ligand 2; NOS3 nitric oxide synthase 3; OR, odds ratio; 95%CI, 95% confidence interval; p-value, level of significance.
aOR and p-value of adjusted model by age and gender.
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suggested a beneficial effect of blocking the action of
CCL2 on diabetic nephropathy and renal function
through anti-fibrotic effects [17]. By analyzing the
CCL2 sequence via PATROCLES, we have found
that the C allele of rs4586 generates a putative target
site (TGCTGCTA) for six different microRNAs
(hsa-miR-15a/15b/16/195/424/497), whereas the
T allele disrupt this target site and consequently
none of these microRNAs target this sequence.
MicroRNAs are small RNA molecules
(22 nucleotides) that have a great impact on
posttranscriptional regulation and potentially large
relevance to complex diseases. When a microRNA
attaches to its target, it can silence expression via
mRNA degradation or by preventing mRNA
translation [18]. Therefore we could hypothesize
that C allele might exert its beneficial effect by
binding a microRNA and blocking the transcription
of CCL2 gene.
On the other hand, rs301640 and rs7830 polymorph-
isms indicated susceptibility to ESRD:
a) rs301640 (A/G) is a SNP located on chromosome
13, in an intergenic region between the eukaryotic
translation initiation factor 4A1 pseudogene 6
(EIF4A1P6) and the gene encoding hsa-miR-3169.
This SNP is located within a binding site for the
transcription factor STAT4. In our study, the
presence of each additional copy of A allele was
associated with increased odds of ESRD. By using
PROMO software [19,20], we found that the A allele
might disrupt the STAT4 binding site, which could
potentially modify a distal enhancer. STAT4 plays an
important role in Th1 differentiation by transmitting
IL-12 signals to produce IFN-γ [21], which could
induce pro-inflammatory cytokines leading to injury
in target tissues.
b) rs7830 (G/T) is located in a region that belongs to
two different genes. The sense strand corresponds to
intron 26-27 of the NOS3 gene, whereas theantisense strand matches with the 3´-UTR of the
autophagy related 9 homolog B (ATG9B) gene.
On the one hand, NOS3 encodes for an enzyme that
generates NO in endothelial cells and is involved in
the regulation of vascular function [22]. On the
other hand, ATG9B encodes for a protein required
for autophagy in several eukaryotic organisms,
although its entire function is unknown [23]. In our
study, the T allele of rs7830 was associated with
ESRD. We hypothesize that the effects of rs7830 on
ESRD might be due to NOS3 rather than ATG9B.
In fact, polymorphisms in NOS3 have been
associated with atherosclerotic vascular diseases
[24], renal dysfunction [25], and advanced diabetic
nephropathy [26]. Moreover, this SNP seems to be
located within a silencer motif (TGGGGACT) [27],
where the G to T allele change could disturb the
splicing mechanism in NOS3 leading to different
transcripts [28]. Thus, this change might affect
NOS3 expression and to be associated with the
development of ESRD.
Although these findings have also been supported by
previous studies where the SNPs described above have
been associated with kidney disease or related (Add-
itional file 1: Table S1 Content 1), we could not find any
significant results after applying FDR correction. In
regards to this, since p-value is depending on the sample
size, it may be possible that we have not found any sig-
nificant adjusted p-value because our sample size is not
large enough to detect moderate effects. Thus only big
effects would be detected in small populations. More-
over, it exists some controversy about adjusting the
“p-value” after multiple tests on clinical-orientated stud-
ies [29,30]. In addition, the weak association found for
the studied polymorphisms could be due to an indirect
involvement in ESRD. That is, it cannot be discarded
that these SNPs might be in linkage disequilibrium with
more powerful polymorphisms associated with ESRD.
Another limitation of our study was that although we
tried to select individuals for control-group with similar
age to case-group, the comparison between means was
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We think that these differences are so slight that have a
low clinical significance. However, logistic regression
analysis was adjusted by age in order to avoid possible
age interferences.
Therefore, this is a preliminary study which could be
considered to generate hypothesis for future studies. In
fact, the association of these SNPs with ESRD needs to
be confirmed by replicating studies with a larger sample
size, as well as functional studies should be performed in
order to get further insights into ESRD susceptibility.
Moreover, it will be interesting to include in the future
some factors which may also influence ESRD develop-
ment (diabetes, dyslipidemia, smoking, etc.) which could
not be collected in this study. Besides, those patients with
ESRD who are receiving dialysis and/or have not yet
received kidney transplant should also be taken into ac-
count in further studies because they could carry on
different genotypes.Conclusions
In conclusion, our preliminary data suggest that four
polymorphisms (rs1801275, rs301640, rs4586, rs7830)
related to inflammatory and immunity processes showed
an association with protection or development of ESRD.
These results could help to predict the risk of developing
the disease, and also to improve the understanding of the
pathways involved in the disease pathogenesis.
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